Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells in Autoimmune Diseases
NCT06888973Phase 2Enrolling by invitation
- Sponsor
- National Institute of Blood and Marrow Transplant
- Start
- Feb 2025
- Primary completion
- Feb 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of mesenchymal stem cells in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), sponsored by National Institute of Blood and Marrow Transplant. Started Feb 2025; status: enrolling by invitation.
02
Drugs
mesenchymal stem cells
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)systemic sclerosis (SSc)ankylosing spondylitis (AS)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT06888973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888973.